MaltSci 麦伴科研

Appearance

Popular Reports / psychiatry

This report is written by MaltSci based on the latest literature and research findings

How does ketamine treat treatment-resistant depression? ​

Abstract ​

Treatment-resistant depression (TRD) is a major challenge in psychiatry, affecting approximately one-third of patients with major depressive disorder who do not respond adequately to conventional antidepressant therapies. Recent research has highlighted ketamine, traditionally an anesthetic, as a promising therapeutic agent for TRD due to its rapid antidepressant effects and unique mechanisms of action. Ketamine primarily functions as an antagonist of the N-methyl-D-aspartate (NMDA) receptor, which enhances glutamatergic neurotransmission and promotes neuroplasticity. Clinical trials have demonstrated that ketamine can induce significant reductions in depressive symptoms within hours of administration, with approximately 45% of patients showing a response and 30% achieving remission. Various administration routes, including intravenous and intranasal methods, have been explored, with intranasal esketamine receiving FDA approval for TRD. However, concerns regarding safety, side effects, and potential misuse necessitate careful consideration in clinical practice. Ketamine's ability to rapidly alleviate depressive symptoms, coupled with its distinct mechanism of action, positions it as a transformative option in the treatment of TRD, warranting further research to optimize its use and explore alternative rapid-acting antidepressants.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Overview of Treatment-Resistant Depression
    • 2.1 Definition and Prevalence of TRD
    • 2.2 Current Treatment Options and Limitations
  • 3 Mechanism of Action of Ketamine
    • 3.1 NMDA Receptor Antagonism
    • 3.2 Impact on Glutamate and Neuroplasticity
  • 4 Clinical Efficacy of Ketamine in TRD
    • 4.1 Evidence from Clinical Trials
    • 4.2 Comparison with Traditional Antidepressants
  • 5 Administration Routes and Treatment Protocols
    • 5.1 Intravenous Ketamine Infusions
    • 5.2 Intranasal Ketamine and Other Delivery Methods
  • 6 Safety and Side Effects of Ketamine
    • 6.1 Common Adverse Effects
    • 6.2 Long-term Safety Considerations
  • 7 Conclusion

1 Introduction ​

Treatment-resistant depression (TRD) poses a significant challenge within the field of psychiatry, affecting a substantial portion of individuals who do not achieve adequate response to conventional antidepressant therapies. The prevalence of TRD is estimated to be as high as 30% among those diagnosed with major depressive disorder, highlighting the urgent need for effective treatment options that can address this critical gap in mental health care [1][2]. In recent years, ketamine, a dissociative anesthetic traditionally used in surgical settings, has emerged as a novel and promising therapeutic agent for TRD. Its rapid antidepressant effects, often observed within hours of administration, mark a significant departure from the delayed onset of traditional antidepressants, which typically require weeks to manifest clinical benefits [3][4].

The significance of ketamine as a treatment for TRD lies not only in its speed of action but also in its unique mechanism of action, which diverges from the monoamine hypothesis that has historically dominated antidepressant development [2]. Ketamine primarily functions as an antagonist of the N-methyl-D-aspartate (NMDA) receptor, influencing glutamatergic neurotransmission, which is increasingly recognized as a critical factor in the pathophysiology of depression [5][6]. Moreover, ketamine has been shown to promote neuroplasticity and synaptogenesis, offering potential insights into its long-lasting effects [1][7]. This review aims to explore the pharmacological properties of ketamine, its clinical efficacy in treating TRD, and the neurobiological mechanisms that underlie its antidepressant effects.

Currently, research on ketamine has expanded to include various administration routes, such as intravenous and intranasal delivery, each with its own implications for treatment protocols [2][8]. The recent FDA approval of esketamine, the S-enantiomer of ketamine, for TRD underscores the growing recognition of ketamine's potential in clinical settings [2]. However, the treatment landscape remains complex, as clinicians must navigate concerns regarding safety, side effects, and the potential for misuse [4][9]. Therefore, understanding the safety profile and adverse effects associated with ketamine treatment is crucial for its integration into standard psychiatric practice [3][7].

The organization of this review will proceed as follows: first, we will provide an overview of TRD, including its definition, prevalence, and current treatment options, along with their limitations. Next, we will delve into the mechanisms of action of ketamine, highlighting its NMDA receptor antagonism and effects on glutamate and neuroplasticity. Following this, we will present evidence from clinical trials that demonstrate ketamine's efficacy in treating TRD and compare it to traditional antidepressants. We will then examine the various administration routes and treatment protocols for ketamine, focusing on intravenous infusions and intranasal methods. Finally, we will discuss the safety and side effects associated with ketamine use, including common adverse effects and long-term safety considerations.

By synthesizing current research findings, this review aims to provide a comprehensive overview of how ketamine can effectively treat TRD, emphasizing its potential as a transformative therapy in psychiatric care. The exploration of ketamine's multifaceted actions not only sheds light on its therapeutic promise but also opens avenues for future research into innovative treatment strategies for depression.

2 Overview of Treatment-Resistant Depression ​

2.1 Definition and Prevalence of TRD ​

Treatment-resistant depression (TRD) is defined as a major depressive disorder that does not respond adequately to at least two different antidepressant treatments, typically involving selective serotonin reuptake inhibitors (SSRIs) or other conventional antidepressants. It is a significant clinical challenge, as approximately one-third of individuals with major depressive disorder are classified as having TRD, highlighting the limitations of traditional monoaminergic therapeutic strategies. This condition not only imposes a substantial burden on patients but also has considerable implications for healthcare systems and society at large.

The prevalence of TRD is a pressing concern, as many patients experience chronic and debilitating symptoms that persist despite multiple treatment attempts. This non-responsiveness to conventional therapies necessitates the exploration of alternative treatment options, leading to the investigation of ketamine as a novel therapeutic agent. Ketamine, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, has garnered attention due to its unique mechanism of action and rapid antidepressant effects.

Ketamine is administered at subanesthetic doses and has been shown to produce rapid (often within hours) and sustained antidepressant effects in patients with TRD. The mechanism underlying these effects is complex and multifaceted. Primarily, ketamine's action is mediated through its antagonistic effects on the NMDA receptor, which is part of the glutamatergic system that plays a critical role in synaptic plasticity and neuroplasticity. This modulation is believed to enhance the release of brain-derived neurotrophic factor (BDNF), a key protein involved in neuronal growth and survival, thereby promoting neurogenesis and synaptic connectivity, which are often impaired in depression [2][3].

In addition to its effects on the glutamatergic system, ketamine also exhibits anti-inflammatory properties, which may be particularly relevant for patients with elevated inflammatory markers. Inflammation is increasingly recognized as a contributing factor to the pathophysiology of depression, and ketamine's ability to reduce inflammation could help improve outcomes for those with TRD [1][5].

Moreover, ketamine's metabolites, such as (2R,6R)-hydroxynorketamine, have also been shown to possess antidepressant effects, potentially providing additional avenues for treatment that minimize adverse effects commonly associated with ketamine itself [4][10]. These metabolites may engage in mechanisms that enhance synaptic function and promote resilience against stress, which are critical for alleviating depressive symptoms [6].

In summary, ketamine represents a promising alternative for the treatment of treatment-resistant depression, leveraging its rapid-acting properties and multifaceted mechanisms that involve modulation of the glutamatergic system, promotion of neuroplasticity, and reduction of inflammation. Its unique pharmacological profile not only challenges traditional views on depression treatment but also opens new avenues for understanding and addressing the underlying neurobiological mechanisms of this complex disorder.

2.2 Current Treatment Options and Limitations ​

Treatment-resistant depression (TRD) is a significant challenge in psychiatric care, affecting approximately one-third of individuals diagnosed with major depressive disorder (MDD). Traditional antidepressants, primarily based on the monoamine hypothesis, often fail to achieve symptom remission in these patients, necessitating the exploration of alternative therapeutic options. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has emerged as a groundbreaking treatment for TRD, demonstrating rapid and robust antidepressant effects within hours of administration.

Ketamine's mechanism of action is complex and multifaceted. Unlike conventional antidepressants, which typically take weeks to exert their effects, ketamine can induce a significant reduction in depressive symptoms within a few hours. This rapid action is believed to be mediated primarily through its antagonistic effects on NMDA receptors, which play a crucial role in glutamatergic neurotransmission. By blocking NMDA receptors, ketamine enhances the release of glutamate, a key excitatory neurotransmitter, which subsequently activates α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. This cascade of events leads to increased synaptic plasticity and neurogenesis, processes that are often impaired in individuals with depression[2][5].

Furthermore, ketamine has been shown to possess anti-inflammatory properties, which may contribute to its antidepressant effects. Inflammation and immune system activation are implicated in the pathophysiology of depression, and ketamine appears to reduce levels of pro-inflammatory cytokines, thereby alleviating some of the inflammatory burden associated with TRD[3][5]. The nuclear factor kappa B (NF-κB) pathway has been identified as a target for ketamine's anti-inflammatory actions, suggesting that the drug's ability to modulate inflammation may enhance its therapeutic efficacy in patients with elevated inflammatory markers[5].

Despite its promising effects, ketamine is not without limitations. The potential for side effects, including dissociative symptoms and cognitive impairments, raises concerns regarding its long-term use[6]. Moreover, there is a notable variability in patient response, with approximately 50% of individuals with TRD not responding to ketamine treatment[11]. This underscores the necessity for ongoing research to identify biomarkers that can predict response to ketamine and to explore the underlying mechanisms of its antidepressant effects.

Current treatment options for TRD include various pharmacological approaches such as augmentation strategies with traditional antidepressants, the use of atypical antipsychotics, and other novel agents like esketamine, the S-enantiomer of ketamine, which has been approved for use in conjunction with oral antidepressants. However, these options often still fall short in providing adequate relief for a substantial number of patients[1].

In conclusion, ketamine represents a novel and effective treatment for TRD, operating through mechanisms distinct from those of traditional antidepressants. Its rapid onset of action and potential to address the inflammatory aspects of depression make it a unique therapeutic option. However, the challenges associated with its side effects and variable efficacy highlight the need for further research to optimize its use and explore alternative rapid-acting antidepressants with improved safety profiles.

3 Mechanism of Action of Ketamine ​

3.1 NMDA Receptor Antagonism ​

Ketamine exerts its rapid antidepressant effects primarily through its action as a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, which is a subtype of glutamate receptor. This mechanism is distinct from traditional antidepressants that primarily target monoaminergic systems, and it has opened new avenues for treating treatment-resistant depression (TRD).

The administration of ketamine leads to a swift and significant reduction in depressive symptoms, often within hours, which contrasts sharply with the delayed onset of conventional antidepressants that may take weeks to exhibit therapeutic effects. Clinical studies have shown that a single subanesthetic dose of ketamine can produce a rapid antidepressant response in patients with TRD, reducing suicidal ideation and improving overall mood [4][12].

The underlying mechanism of action is believed to involve several interconnected pathways. Firstly, ketamine's antagonism of NMDA receptors disrupts the normal excitatory neurotransmission mediated by glutamate. This blockade is hypothesized to result in a cascade of neurochemical events that enhance synaptic plasticity and promote synaptogenesis, particularly in brain regions implicated in mood regulation, such as the prefrontal cortex [13][14].

Specifically, the inhibition of NMDA receptors is thought to lead to the activation of the mammalian target of rapamycin (mTOR) signaling pathway. Activation of mTOR is associated with increased synaptic signaling proteins and the formation of new synapses, which can counteract the synaptic deficits typically observed in depression [15][16]. Additionally, ketamine's blockade of NMDA receptors may also disinhibit excitatory synaptic transmission by reducing the activity of inhibitory interneurons, thus increasing the overall excitatory drive within cortical and limbic circuits [17].

Moreover, ketamine has been shown to induce rapid increases in brain-derived neurotrophic factor (BDNF) levels, a key protein involved in neuroplasticity. This elevation in BDNF is thought to contribute to the structural and functional neural changes that mediate the antidepressant effects [7][18].

Recent research has also explored the role of ketamine's enantiomers, particularly (R)-ketamine, which exhibits a lower affinity for NMDA receptors but may provide longer-lasting antidepressant effects with fewer side effects compared to the racemic mixture or (S)-ketamine [4][19]. The differences in the pharmacological profiles of these enantiomers suggest that they may engage distinct mechanisms of action that warrant further investigation.

In summary, ketamine's treatment of TRD hinges on its ability to rapidly antagonize NMDA receptors, leading to enhanced synaptic plasticity and neurogenesis through mTOR activation and increased BDNF signaling. This unique mechanism positions ketamine as a promising candidate for addressing the unmet needs of patients with treatment-resistant forms of depression.

3.2 Impact on Glutamate and Neuroplasticity ​

Ketamine has emerged as a novel treatment for treatment-resistant depression (TRD), characterized by its rapid antidepressant effects and a unique mechanism of action distinct from traditional antidepressants. The understanding of how ketamine exerts its therapeutic effects is closely linked to its interactions with the glutamatergic system and its ability to enhance neuroplasticity.

Ketamine acts primarily as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, which plays a crucial role in glutamatergic neurotransmission. By inhibiting NMDA receptor activity, ketamine leads to an increase in synaptic glutamate levels, subsequently activating non-NMDA receptors such as α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. This activation triggers a cascade of intracellular signaling pathways that are essential for neuroplasticity, including the mammalian target of rapamycin (mTOR) pathway, which is implicated in synaptogenesis and the formation of new neural connections [1][20].

The role of neuroplasticity in ketamine's mechanism of action is supported by evidence showing that ketamine induces the release of brain-derived neurotrophic factor (BDNF), a key protein that promotes neuronal growth and survival. Elevated BDNF levels have been associated with improved mood and cognitive function in depressed patients [21]. Furthermore, ketamine has been shown to enhance signaling through pathways involving proteins such as eukaryotic elongation factor 2 (eEF2) and glycogen synthase kinase-3 (GSK-3), which contribute to synaptic plasticity and resilience against stress [5][22].

In addition to its effects on glutamate signaling and neuroplasticity, ketamine also exhibits anti-inflammatory properties, which may further contribute to its antidepressant effects. Research indicates that ketamine can reduce inflammation by inhibiting the activation of the nuclear factor kappa B (NF-κB) pathway, thereby decreasing the levels of pro-inflammatory cytokines that are often elevated in patients with depression [5]. This anti-inflammatory action may be particularly beneficial for individuals with TRD, who frequently exhibit higher levels of inflammatory markers [3].

The rapid onset of ketamine's antidepressant effects, often observed within hours of administration, contrasts sharply with the delayed action of conventional antidepressants, which typically require weeks to exert their full effects. This rapid response is thought to be mediated by the immediate changes in synaptic connectivity and neuroplasticity triggered by ketamine's modulation of glutamatergic transmission [5][20].

In summary, ketamine treats treatment-resistant depression through a multifaceted mechanism that includes the modulation of glutamate signaling, enhancement of neuroplasticity, and reduction of inflammation. These combined effects lead to rapid improvements in mood and cognitive function, making ketamine a significant advancement in the pharmacological treatment of depression, particularly for those who do not respond to traditional therapies [3][21].

4 Clinical Efficacy of Ketamine in TRD ​

4.1 Evidence from Clinical Trials ​

Ketamine has emerged as a significant therapeutic option for patients suffering from treatment-resistant depression (TRD), demonstrating rapid and robust antidepressant effects that are distinct from traditional antidepressants. The clinical efficacy of ketamine in treating TRD has been substantiated through numerous studies and meta-analyses, which collectively indicate its effectiveness across varying stages of treatment resistance.

In a systematic review and meta-analysis conducted by Alnefeesi et al. (2022), the mean antidepressant response rate to ketamine in TRD patients was found to be substantial, with 45% of patients responding to treatment and 30% achieving remission. This analysis included 2665 patients across 79 studies, underscoring the considerable impact of ketamine on depressive symptoms, with a Hedges g of symptom improvement measured at 1.44, indicating a large effect size [23].

Further exploring the relationship between the stage of treatment resistance and the efficacy of ketamine, Levinta et al. (2022) reported that ketamine was effective in reducing depressive symptoms across both low and high stages of treatment resistance. However, the effect size and duration of efficacy appeared to be greater in patients with fewer prior treatment failures. The study highlighted that while ketamine remains effective even in more treatment-resistant cases, the likelihood of achieving remission diminishes with an increasing number of failed treatments [24].

In a retrospective chart review involving 424 patients, Oliver et al. (2022) demonstrated significant clinical improvements following ketamine infusions, with a 50% response rate and a 20% remission rate observed within six weeks of initiating treatment. The study also reported a notable reduction in suicidal ideation, with 50% of patients experiencing a decrease in self-harm thoughts after six infusions [25].

Moreover, a study focusing on transitional age youth indicated that ketamine is associated with clinically significant improvements in depression, anxiety, and suicidality, with no significant differences in efficacy observed between younger patients and a matched adult group [26]. This suggests that ketamine's effectiveness is consistent across different age demographics, which is crucial given the increasing interest in its application among younger populations.

The pharmacological action of ketamine, primarily as an NMDA receptor antagonist, leads to increased synaptic plasticity and enhanced AMPA receptor signaling, contributing to its rapid antidepressant effects [18]. This mechanism is believed to induce synaptogenesis, providing a neurobiological basis for the swift alleviation of depressive symptoms observed in clinical settings.

In summary, ketamine's clinical efficacy in treating TRD is well-supported by a robust body of evidence demonstrating significant improvements in depressive symptoms, rapid onset of action, and reductions in suicidal ideation. Despite its promising outcomes, further research is warranted to refine treatment protocols, explore long-term effects, and address potential safety concerns associated with its use.

4.2 Comparison with Traditional Antidepressants ​

Ketamine has emerged as a groundbreaking treatment for treatment-resistant depression (TRD), showcasing a rapid and robust antidepressant effect that contrasts sharply with traditional antidepressants. Conventional antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), typically require weeks to exhibit therapeutic effects, and many patients do not respond adequately, with approximately one-third of individuals suffering from major depressive disorder (MDD) experiencing treatment resistance [1].

In contrast, ketamine, particularly when administered at subanesthetic doses, can alleviate depressive symptoms within hours of administration. This rapid onset is especially significant for patients who are classified as treatment-resistant [27]; ketamine has been shown to produce antidepressant effects that can last up to a week or more following a single dose [2]. The unique efficacy of ketamine in TRD is attributed to its distinct mechanism of action, which differs from the monoamine-focused approaches of traditional therapies. Ketamine acts primarily as an N-methyl-D-aspartate receptor (NMDAR) antagonist, which leads to a cascade of neurobiological changes that are believed to restore synaptic plasticity and improve mood [28].

The antidepressant effects of ketamine are mediated through several complex mechanisms. It is thought to enhance glutamatergic signaling, which plays a critical role in neuroplasticity, a process that is often impaired in individuals with depression [3]. Furthermore, ketamine has been shown to promote the release of brain-derived neurotrophic factor (BDNF) and activate signaling pathways such as the mammalian target of rapamycin (mTOR) [29]. These actions contribute to synaptogenesis and the strengthening of synaptic connections, effectively restoring the integrity of neural circuits that are compromised in depressive states [27].

Additionally, ketamine exhibits anti-inflammatory properties, which may be beneficial for patients with heightened levels of inflammation associated with depression [3]. This dual action of modulating glutamatergic transmission while also addressing inflammation provides a multifaceted approach to treating TRD, highlighting a significant departure from the traditional focus on monoamines [1].

The clinical efficacy of ketamine in TRD has been further supported by numerous studies demonstrating its rapid and sustained effects in various patient populations [30]. For instance, a single infusion of ketamine has been reported to relieve depressive symptoms in treatment-resistant patients within hours, with effects lasting up to two weeks [31]. This rapid response is particularly advantageous in acute psychiatric emergencies, where timely intervention is critical [28].

In summary, ketamine represents a novel and effective therapeutic option for treatment-resistant depression, characterized by its rapid onset of action and unique mechanisms that differ from traditional antidepressants. Its ability to quickly alleviate depressive symptoms and its potential to address underlying neurobiological dysfunctions and inflammation position ketamine as a transformative agent in the management of TRD, offering hope to patients who have not benefited from conventional therapies.

5 Administration Routes and Treatment Protocols ​

5.1 Intravenous Ketamine Infusions ​

Ketamine has emerged as a significant therapeutic option for treatment-resistant depression (TRD), characterized by its rapid onset of action and unique mechanisms compared to traditional antidepressants. The administration of ketamine, particularly through intravenous (IV) infusions, has been extensively studied and documented for its efficacy in this context.

The intravenous administration of ketamine typically involves delivering a subanesthetic dose, commonly set at 0.5 mg/kg of ideal body weight, over a period of approximately 40 minutes. This method allows for direct delivery into the bloodstream, leading to immediate availability and rapid therapeutic effects. Clinical studies have demonstrated that a single IV infusion can result in a robust antidepressant response within hours, with effects lasting up to a week or more[2][32].

Research indicates that ketamine's antidepressant effects are primarily mediated through its action as an N-methyl-D-aspartate (NMDA) receptor antagonist, which leads to increased synaptic plasticity and enhanced glutamatergic neurotransmission. Additionally, ketamine influences other receptors, including α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, and activates downstream signaling pathways that contribute to neurogenesis and synaptogenesis[3][33].

Clinical protocols for IV ketamine infusions have been established to optimize treatment outcomes. These protocols often include a series of infusions, with patients receiving treatments twice weekly for a specified duration, followed by maintenance therapy if clinically indicated. For instance, a study involving patients with ultra-resistant depression noted that participants underwent six infusions over a 2-3 week period, resulting in a response rate of 44% and a remission rate of 16%[34].

Monitoring during IV ketamine administration is crucial, particularly due to the potential for transient hypertensive episodes. Current guidelines recommend regular blood pressure assessments to manage these episodes effectively and ensure patient safety[35]. Despite these considerations, the rapid efficacy of ketamine has made it a valuable option for patients who have not responded to conventional treatments.

In summary, the intravenous administration of ketamine for treatment-resistant depression involves a carefully structured protocol that capitalizes on its rapid onset and unique pharmacological properties. The infusion method not only facilitates effective drug delivery but also enables clinicians to closely monitor patient responses and adjust treatment as necessary, thus enhancing the overall therapeutic experience for individuals suffering from TRD.

5.2 Intranasal Ketamine and Other Delivery Methods ​

Ketamine has emerged as a significant treatment option for patients with treatment-resistant depression (TRD), demonstrating rapid antidepressant effects that are distinct from traditional antidepressants. The administration routes and treatment protocols for ketamine, particularly focusing on intranasal formulations, have been pivotal in its therapeutic application.

The U.S. Food and Drug Administration (FDA) approved an intranasal formulation of esketamine, the S enantiomer of ketamine, in conjunction with an oral antidepressant for treating TRD in 2019. This formulation allows for a non-invasive delivery method that is both convenient and effective. Clinical evidence indicates that intranasal esketamine can provide rapid relief from depressive symptoms, often within two hours, with effects that can last for approximately seven days [2].

In clinical settings, ketamine is typically administered in sub-anesthetic doses. For example, high-dose intravenous ketamine, often ranging from 0.75 to 1 mg/kg, has been shown to produce pronounced clinical effects in TRD patients [36]. The treatment is usually delivered in a series of sessions, often twice weekly for several weeks, followed by maintenance therapy if clinically indicated. A naturalistic cohort study involving 77 patients demonstrated that such a regimen resulted in a significant decrease in depression severity and suicidality, with a response rate of 28.9% and a remission rate of 15% [36].

Moreover, the intranasal route provides several advantages over intravenous administration, including ease of use and the potential for self-administration, which may enhance patient adherence to treatment protocols. This method also circumvents the need for intravenous access, which can be a barrier for some patients [2].

Beyond esketamine, research into other delivery methods for ketamine is ongoing. While intravenous and intranasal routes are the most commonly studied, oral formulations and other innovative delivery systems are being explored to optimize therapeutic outcomes and minimize side effects [10]. For instance, sublingual and oral formulations are under investigation to assess their efficacy and pharmacokinetics in TRD [37].

In summary, ketamine's treatment of TRD primarily involves its administration via intranasal and intravenous routes, with intranasal esketamine providing a rapid and effective option for patients. The established protocols emphasize multiple treatment sessions to achieve sustained antidepressant effects, reflecting a shift in the therapeutic landscape for mood disorders. The ongoing exploration of alternative delivery methods aims to enhance accessibility and patient compliance, potentially broadening the application of ketamine in psychiatric care.

6 Safety and Side Effects of Ketamine ​

6.1 Common Adverse Effects ​

Ketamine has emerged as a novel treatment for treatment-resistant depression (TRD), demonstrating rapid antidepressant effects, often within hours of administration. However, its use is accompanied by a range of potential adverse effects and safety concerns.

Common adverse effects associated with ketamine treatment include dissociative symptoms, cognitive impairment, and increased risk of abuse. The dissociative effects, characterized by alterations in perception and consciousness, are particularly noteworthy. These effects can be distressing for some patients, although they are typically transient. Cognitive impairment may manifest as difficulties in attention, memory, and executive function, raising concerns about the long-term cognitive safety of repeated ketamine use. The potential for abuse is another significant concern, as ketamine is known to be misused recreationally, which complicates its clinical application in psychiatric settings [38].

In clinical practice, while ketamine is generally well-tolerated, the side effects can vary based on individual patient factors, including the dosing regimen and the presence of comorbid conditions. The use of lower doses or alternative formulations, such as (R)-ketamine, has been suggested as a strategy to mitigate some of these adverse effects while maintaining antidepressant efficacy [4].

Additionally, ketamine's mechanism of action, primarily as an N-methyl-D-aspartate (NMDA) receptor antagonist, is associated with rapid neuroplastic changes that underlie its antidepressant effects. However, these mechanisms also involve complex interactions with various neurotransmitter systems, which can contribute to its side effect profile [2].

In summary, while ketamine offers a promising alternative for patients with TRD, its safety profile necessitates careful consideration and monitoring for adverse effects, particularly regarding cognitive function and the risk of misuse. Ongoing research aims to better understand these effects and to develop strategies that maximize therapeutic benefits while minimizing risks [3][4][5].

6.2 Long-term Safety Considerations ​

Ketamine has emerged as a novel treatment option for treatment-resistant depression (TRD), demonstrating rapid antidepressant effects that are distinct from traditional antidepressants. Its mechanism of action primarily involves the antagonism of the N-methyl-D-aspartate (NMDA) receptor, which is part of the glutamatergic system. This action is thought to enhance synaptic connectivity and promote neuroplasticity, thereby alleviating depressive symptoms within hours of administration [2][3][9].

In terms of safety, ketamine is generally well tolerated at low doses, with a favorable safety profile observed during short-term treatments. Adverse effects commonly reported include transient dissociative symptoms, cognitive impairment, and increased blood pressure, particularly at higher doses [6][39]. Long-term safety remains a critical concern, especially given the potential for cognitive dysfunction and neurotoxicity associated with prolonged use. The risk of misuse and dependence is also notable, as ketamine is a substance that has been abused recreationally [38][39].

A study assessing the long-term effects of oral ketamine in an outpatient setting indicated a significant reduction in psychiatric hospital admissions and inpatient days, with no serious adverse events reported [40]. This suggests that with careful monitoring and appropriate dosing, ketamine can be a safe adjunct in managing TRD, although more extensive studies are necessary to fully understand its long-term safety profile.

Additionally, (R)-ketamine, an enantiomer of ketamine, has shown promise in providing similar antidepressant effects with potentially fewer side effects compared to the racemic mixture [6]. Research indicates that (R)-ketamine may be associated with lower risks of adverse effects and could be a safer alternative for long-term treatment strategies in patients with TRD [9].

In conclusion, while ketamine presents a groundbreaking approach to treating TRD with its rapid onset of action, ongoing evaluation of its long-term safety and efficacy is essential to establish it as a standard treatment modality. Future research should focus on optimizing dosing regimens, identifying biomarkers for response, and developing next-generation antidepressants that harness the beneficial effects of ketamine while minimizing risks [41][42].

7 Conclusion ​

Ketamine has emerged as a transformative treatment option for treatment-resistant depression (TRD), demonstrating rapid and robust antidepressant effects that diverge significantly from traditional therapies. The exploration of ketamine's unique mechanisms of action, primarily its NMDA receptor antagonism and its influence on glutamatergic neurotransmission, highlights its potential to address the neurobiological underpinnings of depression. Despite its promising efficacy, the treatment landscape remains complex, with considerations regarding safety, side effects, and the potential for misuse. Ongoing research is essential to refine treatment protocols, explore alternative administration routes, and identify biomarkers that predict patient response to ketamine. Future studies should also focus on the long-term safety profile of ketamine and the development of novel compounds that harness its rapid-acting properties while minimizing adverse effects. This comprehensive understanding will ultimately enhance the integration of ketamine into standard psychiatric practice and improve outcomes for individuals suffering from TRD.

References ​

  • [1] Wenyan Cui;Yuping Ning;Wu Hong;Ju Wang;Zhening Liu;Ming D Li. Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine's Antidepressant Effect.. Molecular neurobiology(IF=4.3). 2019. PMID:30140973. DOI: 10.1007/s12035-018-1306-3.
  • [2] Joydip Das. Repurposing of Drugs-The Ketamine Story.. Journal of medicinal chemistry(IF=6.8). 2020. PMID:32915563. DOI: 10.1021/acs.jmedchem.0c01193.
  • [3] Marta Jóźwiak-Bębenista;Paulina Sokołowska;Anna Wiktorowska-Owczarek;Edward Kowalczyk;Monika Sienkiewicz. Ketamine - A New Antidepressant Drug with Anti-Inflammatory Properties.. The Journal of pharmacology and experimental therapeutics(IF=3.8). 2024. PMID:37977808. DOI: 10.1124/jpet.123.001823.
  • [4] Ellen Scotton;Bárbara Antqueviezc;Mailton França de Vasconcelos;Giovana Dalpiaz;Luiza Paul Géa;Jéferson Ferraz Goularte;Rafael Colombo;Adriane Ribeiro Rosa. Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers.. Biochemical pharmacology(IF=5.6). 2022. PMID:35182519. DOI: 10.1016/j.bcp.2022.114963.
  • [5] Paulina Sokołowska;Michał Seweryn Karbownik;Marta Jóźwiak-Bębenista;Maria Dobielska;Edward Kowalczyk;Anna Wiktorowska-Owczarek. Antidepressant mechanisms of ketamine's action: NF-κB in the spotlight.. Biochemical pharmacology(IF=5.6). 2023. PMID:37952898. DOI: 10.1016/j.bcp.2023.115918.
  • [6] Kai Zhang;Yitan Yao;Kenji Hashimoto. Ketamine and its metabolites: Potential as novel treatments for depression.. Neuropharmacology(IF=4.6). 2023. PMID:36354092. DOI: 10.1016/j.neuropharm.2022.109305.
  • [7] Tahani K Alshammari. The Ketamine Antidepressant Story: New Insights.. Molecules (Basel, Switzerland)(IF=4.6). 2020. PMID:33297563. DOI: 10.3390/molecules25235777.
  • [8] Tung-Ping Su;Li-Kai Cheng;Pei-Chi Tu;Li-Fen Chen;Wei-Chen Lin;Cheng-Ta Li;Ya-Mei Bai;Shih-Jen Tsai;Mu-Hong Chen. Low-dose ketamine improved brain network integrity among patients with treatment-resistant depression and suicidal ideation.. Psychiatry research(IF=3.9). 2025. PMID:39889566. DOI: 10.1016/j.psychres.2025.116377.
  • [9] Luke A Jelen;James M Stone. Ketamine for depression.. International review of psychiatry (Abingdon, England)(IF=3.4). 2021. PMID:33569971. DOI: 10.1080/09540261.2020.1854194.
  • [10] Evan M Hess;Lace M Riggs;Michael Michaelides;Todd D Gould. Mechanisms of ketamine and its metabolites as antidepressants.. Biochemical pharmacology(IF=5.6). 2022. PMID:34968492. DOI: 10.1016/j.bcp.2021.114892.
  • [11] Ji-Woon Kim;Joachim Herz;Ege T Kavalali;Lisa M Monteggia. A key requirement for synaptic Reelin signaling in ketamine-mediated behavioral and synaptic action.. Proceedings of the National Academy of Sciences of the United States of America(IF=9.1). 2021. PMID:33975959. DOI: 10.1073/pnas.2103079118.
  • [12] Mark J Niciu;Ioline D Henter;David A Luckenbaugh;Carlos A Zarate;Dennis S Charney. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.. Annual review of pharmacology and toxicology(IF=13.1). 2014. PMID:24392693. DOI: 10.1146/annurev-pharmtox-011613-135950.
  • [13] Shiyun Lv;Kejie Yao;Youyi Zhang;Shujia Zhu. NMDA receptors as therapeutic targets for depression treatment: Evidence from clinical to basic research.. Neuropharmacology(IF=4.6). 2023. PMID:36539011. DOI: 10.1016/j.neuropharm.2022.109378.
  • [14] Nanxin Li;Boyoung Lee;Rong-Jian Liu;Mounira Banasr;Jason M Dwyer;Masaaki Iwata;Xiao-Yuan Li;George Aghajanian;Ronald S Duman. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.. Science (New York, N.Y.)(IF=45.8). 2010. PMID:20724638. DOI: 10.1126/science.1190287.
  • [15] Ronald S Duman;Nanxin Li;Rong-Jian Liu;Vanja Duric;George Aghajanian. Signaling pathways underlying the rapid antidepressant actions of ketamine.. Neuropharmacology(IF=4.6). 2012. PMID:21907221. DOI: 10.1016/j.neuropharm.2011.08.044.
  • [16] M M Harraz;R Tyagi;P Cortés;S H Snyder. Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation.. Molecular psychiatry(IF=10.1). 2016. PMID:26782056. DOI: 10.1038/mp.2015.211.
  • [17] Oliver H Miller;Jacqueline T Moran;Benjamin J Hall. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition.. Neuropharmacology(IF=4.6). 2016. PMID:26211972. DOI: .
  • [18] Giacomo Salvadore;Jaskaran B Singh. Ketamine as a fast acting antidepressant: current knowledge and open questions.. CNS neuroscience & therapeutics(IF=5.0). 2013. PMID:23578128. DOI: 10.1111/cns.12103.
  • [19] Hana Shafique;Julie C Demers;Julia Biesiada;Lalit K Golani;Rok Cerne;Jodi L Smith;Marta Szostak;Jeffrey M Witkin. (R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders.. International journal of molecular sciences(IF=4.9). 2024. PMID:38928508. DOI: 10.3390/ijms25126804.
  • [20] Arpan Dutta;Shane McKie;J F William Deakin. Ketamine and other potential glutamate antidepressants.. Psychiatry research(IF=3.9). 2015. PMID:25467702. DOI: 10.1016/j.psychres.2014.10.028.
  • [21] Melody J Y Kang;Emily Hawken;Gustavo Hector Vazquez. The Mechanisms Behind Rapid Antidepressant Effects of Ketamine: A Systematic Review With a Focus on Molecular Neuroplasticity.. Frontiers in psychiatry(IF=3.2). 2022. PMID:35546951. DOI: 10.3389/fpsyt.2022.860882.
  • [22] Gianluca Serafini;Robert H Howland;Fabiana Rovedi;Paolo Girardi;Mario Amore. The role of ketamine in treatment-resistant depression: a systematic review.. Current neuropharmacology(IF=5.3). 2014. PMID:25426012. DOI: 10.2174/1570159X12666140619204251.
  • [23] Yazen Alnefeesi;David Chen-Li;Ella Krane;Muhammad Youshay Jawad;Nelson B Rodrigues;Felicia Ceban;Joshua D Di Vincenzo;Shakila Meshkat;Roger C M Ho;Hartej Gill;Kayla M Teopiz;Bing Cao;Yena Lee;Roger S McIntyre;Joshua D Rosenblat. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis.. Journal of psychiatric research(IF=3.2). 2022. PMID:35688035. DOI: 10.1016/j.jpsychires.2022.04.037.
  • [24] Anastasia Levinta;Shakila Meshkat;Roger S McIntyre;Cameron Ho;Leanna M W Lui;Yena Lee;Rodrigo B Mansur;Kayla M Teopiz;Nelson B Rodrigues;Joshua D Di Vincenzo;Felicia Ceban;Joshua D Rosenblat. The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review.. Journal of affective disorders(IF=4.9). 2022. PMID:36049604. DOI: 10.1016/j.jad.2022.08.050.
  • [25] Patrick A Oliver;Andrew D Snyder;Richard Feinn;Stanislav Malov;Gray McDiarmid;Albert J Arias. Clinical Effectiveness of Intravenous Racemic Ketamine Infusions in a Large Community Sample of Patients With Treatment-Resistant Depression, Suicidal Ideation, and Generalized Anxiety Symptoms: A Retrospective Chart Review.. The Journal of clinical psychiatry(IF=4.6). 2022. PMID:36112599. DOI: .
  • [26] Noah Chisamore;Kevork Danayan;Nelson B Rodrigues;Joshua D Di Vincenzo;Shakila Meshkat;Zoe Doyle;Rodrigo Mansur;Lee Phan;Farhan Fancy;Edmond Chau;Aniqa Tabassum;Kevin Kratiuk;Anil Arekapudi;Roger S McIntyre;Joshua D Rosenblat. Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.. Journal of psychopharmacology (Oxford, England)(IF=5.5). 2023. PMID:37194253. DOI: 10.1177/02698811231171531.
  • [27] Lace M Riggs;Todd D Gould. Ketamine and the Future of Rapid-Acting Antidepressants.. Annual review of clinical psychology(IF=16.5). 2021. PMID:33561364. DOI: 10.1146/annurev-clinpsy-072120-014126.
  • [28] Philip Borsellino;Reese I Krider;Deanna Chea;Ryan Grinnell;Thomas A Vida. Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression.. Pharmaceuticals (Basel, Switzerland)(IF=4.8). 2023. PMID:37242525. DOI: 10.3390/ph16050742.
  • [29] Kenji Hashimoto. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.. Biochemical pharmacology(IF=5.6). 2020. PMID:32224141. DOI: 10.1016/j.bcp.2020.113935.
  • [30] Jenessa N Johnston;Bashkim Kadriu;Christoph Kraus;Ioline D Henter;Carlos A Zarate. Ketamine in neuropsychiatric disorders: an update.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology(IF=7.1). 2024. PMID:37340091. DOI: 10.1038/s41386-023-01632-1.
  • [31] Caroline A Browne;Irwin Lucki. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants.. Frontiers in pharmacology(IF=4.8). 2013. PMID:24409146. DOI: 10.3389/fphar.2013.00161.
  • [32] Lily R Aleksandrova;Anthony G Phillips;Yu Tian Wang. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism.. Journal of psychiatry & neuroscience : JPN(IF=3.3). 2017. PMID:28234212. DOI: 10.1503/jpn.160175.
  • [33] Bashkim Kadriu;Laura Musazzi;Ioline D Henter;Morgan Graves;Maurizio Popoli;Carlos A Zarate. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.. The international journal of neuropsychopharmacology(IF=3.7). 2019. PMID:30445512. DOI: 10.1093/ijnp/pyy094.
  • [34] Rejish K Thomas;Glen Baker;John Lind;Serdar Dursun. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness.. Journal of psychopharmacology (Oxford, England)(IF=5.5). 2018. PMID:30182797. DOI: 10.1177/0269881118793104.
  • [35] Ryan Yip;Jennifer Swainson;Atul Khullar;Roger S McIntyre;Kevin Skoblenick. Intravenous ketamine for depression: A clinical discussion reconsidering best practices in acute hypertension management.. Frontiers in psychiatry(IF=3.2). 2022. PMID:36245888. DOI: 10.3389/fpsyt.2022.1017504.
  • [36] Stefan Vestring;Viktoria Galuba;Elisa Kern;Sabine Voita;Franziska Berens;Danial Nasiri;Katharina Domschke;Claus Normann. Ketamine in multiple treatment-resistant depressed inpatients: A naturalistic cohort study.. Journal of affective disorders(IF=4.9). 2024. PMID:38266928. DOI: 10.1016/j.jad.2024.01.165.
  • [37] Yingliang Dai;Ben J Harrison;Christopher G Davey;Trevor Steward. Towards an expanded neurocognitive account of ketamine's rapid antidepressant effects.. The international journal of neuropsychopharmacology(IF=3.7). 2025. PMID:39921611. DOI: 10.1093/ijnp/pyaf010.
  • [38] Leah Vines;Diana Sotelo;Allison Johnson;Evan Dennis;Peter Manza;Nora D Volkow;Gene-Jack Wang. Ketamine use disorder: preclinical, clinical, and neuroimaging evidence to support proposed mechanisms of actions.. Intelligent medicine(IF=6.9). 2022. PMID:35783539. DOI: 10.1016/j.imed.2022.03.001.
  • [39] Weili Zhu;Zengbo Ding;Yinan Zhang;Jie Shi;Kenji Hashimoto;Lin Lu. Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant.. Neuroscience bulletin(IF=5.8). 2016. PMID:27878517. DOI: 10.1007/s12264-016-0081-2.
  • [40] John Hartberg;Simone Garrett-Walcott;Angelo De Gioannis. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.. Psychopharmacology(IF=3.3). 2018. PMID:29151192. DOI: 10.1007/s00213-017-4786-3.
  • [41] Ezio Carboni;Anna R Carta;Elena Carboni;Antonello Novelli. Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?. Frontiers in neuroscience(IF=3.2). 2021. PMID:33994933. DOI: 10.3389/fnins.2021.657714.
  • [42] Katelyn Halpape;Raelle Pashovitz;Annabelle Wanson;Monika Hooper;Evyn M Peters. Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant depression: a naturalistic feasibility study.. BMC psychiatry(IF=3.6). 2025. PMID:39773202. DOI: 10.1186/s12888-024-06448-x.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Ketamine · Treatment-Resistant Depression · NMDA Receptor Antagonist · Neuroplasticity · Clinical Trials

© 2025 MaltSci